Satellos Bioscience Inc. (Satellos), a biotech company developing new small-molecule therapeutic approaches to improve the treatment of muscle diseases, appointed Wildon Farwell, M.D., MPH, as chief medical officer (CMO). Farwell succeeds Jordan Dubow, MD, who has served as Satellos’ part-time CMO since January 2024. Dubow will continue to serve as a consultant to Satellos and chair of its Clinical Advisory Board. Farwell joins Satellos from Dyne Therapeutics, where he most recently served...